QOR.ASX CLU.ASX RMD.ASX OCC.ASX HYD.ASX

Market Roundup: Mergers, Earnings, and Operational Updates

Aura and Qoria to Merge, Creating Global Leader in Online Safety Aura Consolidated Group and Qoria Limited have agreed to merge, with Aura acquiring 100% of Qoria via a scheme of arrangement. Qoria shareholders will receive 1 Aura CHESS Depositary Interest (CDI) for every 17.2 Qoria shares, representing a 35% ownership in the combined entity. Aura has also secured a US$75 million equity placement from existing shareholders at A$12.38 per CDI. The merged entity is expected to have over US$316 million in annual recurring revenue by 2025 and target positive free cash flow from 2026. This transformational combination will establish a world-leading safety and online security platform, unlocking cross-market opportunities and expanding the companies' global reach.

Cluey Halts Art of Smart Acquisition Cluey Ltd has announced it will not proceed with the acquisition of Education Futures Group, the holding company of the Art of Smart group. The transaction did not meet certain conditions precedent, and Cluey has exercised its right to terminate the agreement. Despite the disappointment, Cluey remains committed to its in-person blended learning strategy and will continue to explore synergistic acquisitions to support its growth.

ResMed Reports Strong Q2 Results ResMed Inc. has reported its financial results for the second quarter of fiscal year 2026, delivering robust performance across its business segments. Revenue grew 11% year-over-year, with the Sleep and Breathing Health and Residential Care Software divisions both contributing to the top-line expansion. The company also saw improvements in gross margins and operating income, while maintaining a solid balance sheet and generating strong cash flow. Looking ahead, ResMed expects revenue growth in the high single-digit to low double-digit range and further operating margin expansion for the full fiscal year.

Orthocell Provides US Market Update Orthocell Ltd has shared an update on its progress in the US market, highlighting that its Remplir strategy is on track. The company's market access activities are progressing as planned, and sales in the US continue to build. Orthocell is fully funded and investing in growth to reach profitability, targeting approximately 10,000 Remplir unit sales per annum in the US to reach cash breakeven - a fraction of the sizeable 700,000 annual peripheral nerve repair procedures opportunity.

Hydrix Releases Amended Appendix 4C Hydrix Ltd has released an amended Appendix 4C for the quarter ended 31 December 2025, correcting a typographical error in the previously lodged report. The amended document provides detailed financial information, including receipts from customers, payments, and net cash flows from operating activities.

Qoria Requests Trading Halt Qoria Ltd has requested an immediate trading halt in its securities pending an announcement regarding a potential control transaction and associated capital raising. The halt will remain in place until the earlier of Wednesday, 4 February 2026 or the release of the announcement.